Home Infusion Therapy Services MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy ComponentBy End UserBy Route of Administration
Full title & scope — all 5 axes with their segments
Home Infusion Therapy Services Market Size, Share & Industry Analysis, By Type (Intravenous set, Needleless catheter, Infusion pump), By Application (Chemotherapy, Diabetes, Hydration therapy, Inotropic therapy, Pain management, HIV therapies, Post-transplant therapies, Total parenteral nutrition, Hemophilia therapies, Others), By Component (Devices & Equipment, Consumables, Services), By End User (Home Care Settings, Specialty Pharmacies, Hospital-Based Home Infusion Providers, Skilled Nursing Facilities), By Route of Administration (Central Venous Access, Peripheral Venous Access), and Regional Forecast, 2026-2034
Full table of contents for the published report, chapter by chapter.
- 01By TypeIntravenous set · Needleless catheter · Infusion pump
- 02By ApplicationChemotherapy · Diabetes · Hydration therapy
- 03By ComponentDevices & Equipment · Consumables · Services
- 04By End UserHome Care Settings · Specialty Pharmacies · Hospital-Based Home Infusion Providers
- 05By Route of AdministrationCentral Venous Access · Peripheral Venous Access
- 06By Region
Market Analysis & Outlook
Home infusion therapy services cover intravenous and subcutaneous drug and nutrient administration delivered in a patient's home rather than a hospital or outpatient clinic. The category spans the devices used to deliver therapy, such as infusion pumps, administration sets and needleless connectors, the consumable supplies that support each course of treatment, and the clinical and logistics services, including nursing visits, pharmacy compounding and delivery coordination, that keep a therapy running safely outside a facility. Buyers include home health agencies, specialty pharmacies, hospital-based home infusion programs and the payers that reimburse this care.
The global home infusion therapy services market is valued at USD 42 billion in 2025 and is set to reach USD 91.1 billion by 2034, a compound annual growth rate of 9.04% across the 2026-2034 forecast period. The study tracks the market across USD 27.9 billion in 2020, USD 38.7 billion in 2024, USD 45.6 billion in 2026 and USD 64.4 billion in 2030.
The type mix shifts over the period. Infusion pump is the largest line in 2025 at USD 18.5 billion, a 44.05% share, moving to USD 41.9 billion and 45.99% by 2034. Needleless catheter grows fastest at 9.61%, taking its share from 20.95% to 21.95%, while Intravenous set grows slowest at 7.98%. Share moves toward Needleless catheter and Infusion pump and away from Intravenous set, though no line shrinks in revenue terms.
Cut by application, the largest line is Chemotherapy: 22.14% of 2025 revenue, worth USD 9.3 billion, and 22.94% at USD 20.9 billion by 2034. Diabetes grows faster at 10.12% against 9.41%, moving from 10% of revenue to 10.98% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.
Geographically, 43.3% of 2025 revenue sits in North America (USD 18.2 billion rising to USD 36.4 billion) ahead of Europe at 26.9% and USD 11.3 billion. Latin America is smallest, at 4.3%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates rather than spreading across all five regions.
The 2025 total is triangulated from published sources and category proxies rather than an independently sourced count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, three type lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 42 billion in 2025 to USD 91.1 billion in 2034, a compound annual rate of 9.04%, having reached USD 38.7 billion in 2024 from USD 27.9 billion in 2020.
- Infusion pump is the largest type line at USD 18.5 billion in 2025, a 44.05% share, reaching USD 41.9 billion and 45.99% of revenue by 2034.
- Needleless catheter is the fastest-growing line at 9.61%, lifting its share from 20.95% in 2025 to 21.95% in 2034 and its revenue from USD 8.8 billion to USD 20 billion.
- The bull case puts 2034 revenue at USD 97.9 billion and the bear case at USD 80 billion, either side of the USD 91.1 billion base case, each with its own stated assumption in the full report.
- 43.3% of 2025 revenue is generated in North America, worth USD 18.2 billion and rising to USD 36.4 billion by 2034; Latin America is smallest at 4.3%.
- Within North America, the United States is the worked country example, at USD 14.2 billion in 2025; 78% of regional revenue in the base year, and USD 28 billion by 2034.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By by type
Base year 2025Infusion pump leads with 44.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Read across the forecast period, the global home infusion therapy services market shows movement in three places: type composition, regional weight, and the 9.04% rate applied to the whole.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.
The type mix tilts toward Needleless catheter. 9.61% against 7.98%: that gap, between Needleless catheter and Intravenous set, is the largest on the type axis. By 2034 the two sit at 21.95% and 32.05% of revenue, against 20.95% and 35% in 2025. Revenue rises on both sides; USD 8.8 billion to USD 20 billion and USD 14.7 billion to USD 29.2 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
The regional balance moves. Asia Pacific moves from 21% of revenue in 2025 to 26% in 2034, worth USD 8.8 billion rising to USD 23.7 billion; Latin America moves from 4.3% of revenue in 2025 to 5% in 2034, worth USD 1.8 billion rising to USD 4.6 billion. Against that, North America at 43.3% moving to 40%, Europe at 26.9% moving to 25%, Middle East and Africa at 4.5% moving to 4%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
A continuation, not an inflection. Year by year the total runs USD 27.9 billion in 2020, USD 38.7 billion in 2024, USD 42 billion in 2025, USD 45.6 billion in 2026, USD 64.4 billion in 2030 and USD 91.1 billion in 2034. Against 8.53% through the historical period, the 9.04% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions rather than in whether the market grows at all, which is where the type and regional sections come in.
Market Growth Factors
Needleless catheter carries the market's growth rate
Market Drivers
3- 01Needleless catheter carries the market's growth rate
9.61% growth in Needleless catheter, against 9.04% for the market as a whole, moves it from USD 8.8 billion and 20.95% of revenue in 2025 to USD 20 billion and 21.95% in 2034. Nothing else on the axis grows as fast (Intravenous set manages 7.98%) so the blended 9.04% is carried by this one line rather than shared across them. That makes position on the type axis a growth decision rather than a product one.
- 02The two largest regions hold most of the base
The largest regional base is North America: USD 18.2 billion in 2025 at 43.3% of the global total, USD 36.4 billion by 2034, still 40%. Behind it, Europe holds 26.9%; USD 11.3 billion rising to USD 22.8 billion. Between them they hold most of the base and most of the revenue added over the period, so equal-weighting the regions in a plan misstates where the growth is.
- 03Fifteen years of unbroken growth underpin the forecast
Revenue rose through USD 27.9 billion in 2020, USD 38.7 billion in 2024 and USD 42 billion in 2025, a compound 8.53% across the historical period. The forecast continues at 9.04% to USD 91.1 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 9.04% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Shift of complex infusion therapies from hospital to home settings | High | +14 | High | High | High |
| 2 | Rising chronic disease and long-term therapy volumes (oncology, nutrition support, immunotherapy) | High | +12.5 | High | High | High |
| 3 | Expansion of specialty pharmacy and home infusion provider networks | Medium-High | +9 | High | Medium | Medium |
| 4 | Adoption of smart, connected infusion pumps and remote monitoring | Medium-High | +7.5 | Medium | High | High |
| 5 | Broadening insurance and reimbursement support for home-based care in emerging markets | Medium | +5 | Low | Medium | Medium |
| 6 | Others | Low | +8.1 | Low | Low | Low |
| Total | +56.1 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Reimbursement complexity and payer coverage limits in emerging markets | Medium | −3.5 | Medium | Medium | Low |
| 2 | Clinical risk and complication management burden outside hospital settings | Medium | −2 | Medium | Medium | Medium |
| 3 | Shortage of trained home infusion nursing staff | Medium | −1.5 | High | Medium | Medium |
| Total | −7 | |||||
Drivers contribute 56.1 Billion and restraints remove 7 Billion, a net 49.1 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 9.04% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.
Restraining Factors
Downside case: USD 80 billion rather than USD 91.1 billion by 2034
Market Restraints
2- 01Downside case: USD 80 billion rather than USD 91.1 billion by 2034
The bear case assumes reimbursement policy tightens in key markets and the home infusion nursing shortage persists longer than expected, slowing the pace at which complex therapies shift out of hospital settings. On that assumption 2034 revenue lands at USD 80 billion rather than the USD 91.1 billion base case, from the same USD 42 billion 2025 starting point.
- 02Intravenous set grows below the market rate
With 35% of 2025 revenue (USD 14.7 billion) Intravenous set is where most of the market sits, and it grows at only 7.98% against the market's 9.04%. Revenue still reaches USD 29.2 billion by 2034 and share still falls to 32.05%: a drag on the average rather than a decline.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
What would beat the forecast: the bull case assumes faster payer adoption of home-based infusion reimbursement across major markets and quicker scaling of specialty pharmacy networks, pulling forward volume that would otherwise arrive later in the forecast. That case reaches USD 97.9 billion in 2034 rather than USD 91.1 billion, and it is worth testing against a reader's own read of the market.
- 02The opening is on the type axis, not the regional one
Share on the type axis moves toward Needleless catheter, from 20.95% in 2025 to 21.95% in 2034, on 9.61% growth against the market's 9.04% and revenue rising from USD 8.8 billion to USD 20 billion. Taking position there does not require displacing whoever holds Infusion pump, which is the harder and more expensive fight.
Market Challenges
Revenue is concentrated in Infusion pump
Market Challenges
2- 01Revenue is concentrated in Infusion pump
One line dominates: Infusion pump, at 44.05% of revenue in 2025 and 45.99% in 2034, worth USD 18.5 billion and USD 41.9 billion. That concentration means the market's own forecast is, to a large extent, a forecast for one type line.
- 02North America is largely the United States
North America is worth USD 18.2 billion in 2025 and USD 14.2 billion of that is the United States; 78% of the region, reaching USD 28 billion in 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe market is divided by type and by application, component, end user and route of administration; five axes in all. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market rather than additions to it.
There are three lines on the type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: two gain it, the other gives it up.
By Type · 3 segments
Infusion pump Led by Type in 2025, with Needleless catheter Growing Fastest
- Largest Infusion pump · 44%
- Fastest Needleless catheter · 9.6%
- Moves most Intravenous set · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Intravenous set | $14.70B | 35% | $29.20B | 32%-3 | 8% |
| Needleless catheter | $8.80B | 20.9% | $20B | 21.9%+1 | 9.6% |
| Infusion pump | $18.50B | 44% | $41.90B | 46%+1.9 | 9.6% |
Infusion pumps lead the type mix because they anchor the durable equipment cost of every new home infusion setup and carry the highest reimbursed unit value. Needleless catheters grow fastest as infection-control protocols and needlestick-safety requirements push providers toward closed, low-exposure connection systems across a widening range of therapies. Infusion pump remains the largest line through 2034, so the axis changes in proportion rather than in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 10 segments
By Application
- Largest Chemotherapy · 22.1%
- Fastest Diabetes · 10.1%
- Moves most Hydration therapy · -1.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Chemotherapy | $9.30B | 22.1% | $20.90B | 22.9%+0.8 | 9.4% |
| Diabetes | $4.20B | 10% | $10B | 11%+1 | 10.1% |
| Hydration therapy | $5.90B | 14.1% | $11.80B | 12.9%-1.1 | 8% |
| Inotropic therapy | $2.90B | 6.9% | $6.40B | 7%+0.1 | 9.2% |
| Pain management | $5B | 11.9% | $10.90B | 12%+0.1 | 9.1% |
| HIV therapies | $2.50B | 6% | $5.50B | 6%+0.1 | 9.2% |
| Post-transplant therapies | $2.10B | 5% | $4.60B | 5% | 9.1% |
| Total parenteral nutrition | $6.70B | 15.9% | $13.70B | 15%-0.9 | 8.3% |
| Hemophilia therapies | $2.10B | 5% | $4.60B | 5% | 9.1% |
| Others | $1.30B | 3.1% | $2.70B | 3%-0.1 | 8.5% |
2025 to 2034 revenue and share by line: Chemotherapy USD 9.3 billion to USD 20.9 billion (22.14% in 2025), Total parenteral nutrition USD 6.7 billion to USD 13.7 billion (15.95% in 2025), Hydration therapy USD 5.9 billion to USD 11.8 billion (14.05% in 2025), Pain management USD 5 billion to USD 10.9 billion (11.9% in 2025), Diabetes USD 4.2 billion to USD 10 billion (10% in 2025), Inotropic therapy USD 2.9 billion to USD 6.4 billion (6.9% in 2025), HIV therapies USD 2.5 billion to USD 5.5 billion (5.95% in 2025), Post-transplant therapies USD 2.1 billion to USD 4.6 billion (5% in 2025), Hemophilia therapies USD 2.1 billion to USD 4.6 billion (5% in 2025), Others USD 1.3 billion to USD 2.7 billion (3.1% in 2025). Chemotherapy Held the Dominant Share of the Application Segment in 2025 Chemotherapy leads because oncology regimens are the most established candidates for home administration, backed by long clinical familiarity and consistent payer support. Diabetes-related infusion therapies grow fastest as home glycemic management protocols expand alongside rising prevalence and closer integration with remote monitoring tools that make home administration practical for a broader group of patients. The order does not change: Chemotherapy is still largest in 2034, and what moves is how much it holds.
By Component · 3 segments
Devices & Equipment Led by Component in 2025, with Services Growing Fastest
- Largest Devices & Equipment · 40%
- Fastest Services · 9.9%
- Moves most Consumables · -3.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Devices & Equipment | $16.80B | 40% | $37.40B | 41%+1 | 9.3% |
| Consumables | $13.90B | 33.1% | $27.30B | 30%-3.1 | 7.8% |
| Services | $11.30B | 26.9% | $26.40B | 29%+2.1 | 9.9% |
Devices and equipment lead the component split because outfitting each new home patient still starts with an equipment purchase or lease. Services grow fastest as nursing visits, care coordination and pharmacy compounding scale directly with patient volume, increasingly defining the ongoing cost of a home infusion program more than the initial equipment outlay. By 2034 Devices & Equipment is still ahead, making this a shift in weight rather than a change of leader.
By End User · 4 segments
Home Care Settings Both Leads the End user Axis and Grows Fastest on It
- Largest Home Care Settings · 55%
- Fastest Home Care Settings · 9.4%
- Moves most Home Care Settings · +2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Home Care Settings | $23.10B | 55% | $51.90B | 57%+2 | 9.4% |
| Specialty Pharmacies | $9.20B | 21.9% | $19.10B | 21%-0.9 | 8.5% |
| Hospital-Based Home Infusion Providers | $6.30B | 15% | $12.80B | 14.1%-0.9 | 8.2% |
| Skilled Nursing Facilities | $3.40B | 8.1% | $7.30B | 8%-0.1 | 8.9% |
Home care settings lead because payers consistently favor non-facility care for cost containment once a patient is clinically stable enough to leave a hospital or clinic. The same setting also grows fastest, as therapies once considered too complex for the home increasingly become manageable there through better monitoring and trained home nursing support. Home Care Settings remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Route of Administration · 2 segments
Central Venous Access Holds the Largest Route of administration Share and Is Still the Quickest to Grow
- Largest Central Venous Access · 61.9%
- Fastest Central Venous Access · 9.2%
- Moves most Central Venous Access · +1.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Central Venous Access | $26B | 61.9% | $57.40B | 63%+1.1 | 9.2% |
| Peripheral Venous Access | $16B | 38.1% | $33.70B | 37%-1.1 | 8.6% |
Central venous access leads because the higher-acuity, longer-duration therapies that make up most home infusion volume, such as parenteral nutrition and extended antibiotic courses, require reliable long-term access. It also grows fastest as more complex regimens migrate into the home, bringing demand for durable central access rather than short peripheral lines. The order does not change: Central Venous Access is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3.3 points of share move elsewhere by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 43.3%
- By 2034 40%
- Revenue $18.20B → $36.40B
43.3% of the global home infusion therapy services market sits in North America in 2025, worth USD 18.2 billion on the way to USD 36.4 billion by 2034. Among the five regions it ranks first by revenue in both years.
By 2034 the share stands at 40%, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The type mix reported at global level applies here, with Infusion pump the largest line at 44.05% of 2025 revenue and Needleless catheter the fastest-growing at 9.61%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 78% of it, growing 2.0×.
- In region 1 of 2
- Of region 78%
- Of global 33.8%
- Revenue $14.20B → $28B
USD 14.2 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 28 billion by 2034. Because it is 78% of the region in the base year, North America's totals move with this one country rather than with a spread of them. Set against USD 18.2 billion and USD 36.4 billion for the region, it is why this market rather than a smaller one is the one reported in full.
the United States buys along the same lines as the market globally; Infusion pump first at 44.05% of 2025 revenue and 45.99% in 2034, Needleless catheter fastest at 9.61% on a share moving from 20.95% to 21.95%. With 78% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports the United States by type separately.
In the United States, infusion pumps and related durable medical equipment used in home infusion therapy are regulated as medical devices by the Food and Drug Administration, which assigns a device classification and requires premarket clearance or approval before a product can be marketed. Home infusion pharmacies must comply with United States Pharmacopeia sterile compounding standards and state board of pharmacy licensing, while home health agencies delivering infusion services are subject to Medicare conditions of participation and accreditation by bodies such as the Accreditation Commission for Health Care or the Community Health Accreditation Partner. Suppliers must maintain quality system compliance and accurate device labelling throughout distribution.
In the United States the field is ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc.. Two different problems sit on the same axis: holding Infusion pump at 44.05% of 2025 revenue, and taking Needleless catheter while it grows at 9.61%. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 2.0×.
- In region 2 of 2
- Of region 13.2%
- Of global 5.7%
- Revenue $2.40B → $4.70B
Within North America, Canada accounts for 13.2% of regional revenue and 5.7% of the global total, worth USD 2.4 billion in 2025 and USD 4.7 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 1.9 points of share move elsewhere by 2034, while revenue still grows 2.0×.
- Rank 2 of 5
- 2025 share 26.9%
- By 2034 25%
- Revenue $11.30B → $22.80B
26.9% of the global home infusion therapy services market sits in Europe in 2025, worth USD 11.3 billion on the way to USD 22.8 billion by 2034. Among the five regions it ranks second by revenue in both years.
25% of global revenue sits here in 2034, below the 2025 level, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Infusion pump leads here as it does globally, at 44.05% of 2025 revenue, and Needleless catheter again grows fastest at 9.61%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 1.9×.
- In region 1 of 3
- Of region 30.1%
- Of global 8.1%
- Revenue $3.40B → $6.60B
Germany is the largest market within Europe, generating USD 3.4 billion in 2025 and projected to reach USD 6.6 billion by 2034. 30.1% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 11.3 billion in 2025 and USD 22.8 billion in 2034, it is the country the full report breaks out in detail.
Germany buys along the same lines as the market globally; Infusion pump first at 44.05% of 2025 revenue and 45.99% in 2034, Needleless catheter fastest at 9.61% on a share moving from 20.95% to 21.95%. Since 30.1% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for Germany appears on its own in the full report.
In Germany, infusion pumps and related devices used in home infusion therapy fall under the European Union Medical Device Regulation, requiring CE marking through assessment by a notified body before market placement, alongside classification according to intended use and risk. The Federal Institute for Drugs and Medical Devices oversees vigilance and market surveillance, while home infusion pharmacy compounding must conform to the German Pharmacy Operation Ordinance and recognized pharmacopoeial sterile preparation standards. Home care service delivery is governed under the Social Code Book covering statutory health insurance, requiring providers to hold service contracts and meet defined quality and safety requirements before reimbursement is granted.
In Germany the field is ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc.. The commercially relevant division is 44.05% of 2025 revenue in Infusion pump, where the volume is, against 9.61% growth in Needleless catheter, where share moves.
United Kingdom
2nd-largest in Europe, growing 1.9×.
- In region 2 of 3
- Of region 23.9%
- Of global 6.4%
- Revenue $2.70B → $5.20B
Within Europe, the United Kingdom accounts for 23.9% of regional revenue and 6.4% of the global total, worth USD 2.7 billion in 2025 and USD 5.2 billion by 2034.
France
3rd-largest in Europe, growing 1.9×.
- In region 3 of 3
- Of region 15.9%
- Of global 4.3%
- Revenue $1.80B → $3.40B
Within Europe, France accounts for 15.9% of regional revenue and 4.3% of the global total, worth USD 1.8 billion in 2025 and USD 3.4 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5 points of share by 2034, while revenue still grows 2.7×.
- Rank 3 of 5
- 2025 share 21%
- By 2034 26%
- Revenue $8.80B → $23.70B
USD 8.8 billion of 2025 revenue is generated in Asia Pacific, 21% of the global home infusion therapy services market rising to USD 23.7 billion in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Share climbs to 26% by 2034, on growth above the market's own 9.04%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
The type mix reported at global level applies here, with Infusion pump the largest line at 44.05% of 2025 revenue and Needleless catheter the fastest-growing at 9.61%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.6×.
- In region 1 of 3
- Of region 42%
- Of global 8.8%
- Revenue $3.70B → $9.50B
42% of Asia Pacific's base-year revenue comes from China; USD 3.7 billion, rising to USD 9.5 billion by 2034. 42% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 8.8 billion to USD 23.7 billion over the same period, and this is the market carrying the country-level detail in the full report.
China buys along the same lines as the market globally; Infusion pump first at 44.05% of 2025 revenue and 45.99% in 2034, Needleless catheter fastest at 9.61% on a share moving from 20.95% to 21.95%. Its 42% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by type separately.
In China, infusion pumps and other devices used in home infusion therapy are regulated by the National Medical Products Administration, which assigns a risk-based device classification and requires registration certification, along with conformity to national compulsory standards, before a product may be marketed or sold. Home healthcare service providers are subject to oversight by the National Health Commission and local health authorities, which set licensing and staffing requirements for agencies delivering infusion care outside hospital settings. Sterile compounding of infusion medications must follow Chinese Pharmacopoeia standards, and labelling must appear in Chinese with instructions and warnings meeting national requirements for medical products.
Competition in China runs between the suppliers this study tracks: ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc.. Two different problems sit on the same axis: holding Infusion pump at 44.05% of 2025 revenue, and taking Needleless catheter while it grows at 9.61%.
Japan
2nd-largest in Asia Pacific, growing 2.4×.
- In region 2 of 3
- Of region 27.3%
- Of global 5.7%
- Revenue $2.40B → $5.70B
Japan is sized at USD 2.4 billion in 2025, rising to USD 5.7 billion by 2034; 5.7% of global revenue and 27.3% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
India
3rd-largest in Asia Pacific, growing 3.5×.
- In region 3 of 3
- Of region 14.8%
- Of global 3.1%
- Revenue $1.30B → $4.50B
Within Asia Pacific, India accounts for 14.8% of regional revenue and 3.1% of the global total, worth USD 1.3 billion in 2025 and USD 4.5 billion by 2034.
Latin America Market Analysis
The 5th-largest region covered — it picks up 0.7 points of share by 2034, while revenue still grows 2.6×.
- Rank 5 of 5
- 2025 share 4.3%
- By 2034 5%
- Revenue $1.80B → $4.60B
Latin America holds 4.3% of the global home infusion therapy services market in 2025, worth USD 1.8 billion with USD 4.6 billion projected for 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
Its share rises to 5% over the forecast period, on growth above the market's own 9.04%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Segment composition follows the global pattern: Infusion pump largest at 44.05% of 2025 revenue, Needleless catheter fastest at 9.61%. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.4×.
- In region 1 of 2
- Of region 55.6%
- Of global 2.4%
- Revenue $1B → $2.40B
55.6% of Latin America's base-year revenue comes from Brazil; USD 1 billion, rising to USD 2.4 billion by 2034. It accounts for 55.6% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 1.8 billion and USD 4.6 billion for the region, it is why this market rather than a smaller one is the one reported in full.
The type pattern in Brazil is the global one: 44.05% of 2025 revenue in Infusion pump, 45.99% by 2034, against 9.61% growth in Needleless catheter taking it from 20.95% to 21.95%. With 55.6% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Brazil is reported separately in the full report.
In Brazil, infusion pumps and related medical devices used in home infusion therapy are regulated by the National Health Surveillance Agency, known as ANVISA, which requires product registration, risk-based classification, and conformity with national technical standards before market entry. Home care service providers, including those delivering infusion therapy in the patient's residence, must obtain sanitary licensing and comply with ANVISA's regulatory framework governing home healthcare, known as Atenção Domiciliar, which sets requirements for clinical protocols, staffing, and equipment safety. Labelling of devices and medications must be in Portuguese and meet ANVISA's disclosure and safety requirements for home use products.
The suppliers tracked in this study (ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc.) compete in Brazil across the type lines above. Two different problems sit on the same axis: holding Infusion pump at 44.05% of 2025 revenue, and taking Needleless catheter while it grows at 9.61%.
Mexico
2nd-largest in Latin America, growing 2.6×.
- In region 2 of 2
- Of region 27.8%
- Of global 1.2%
- Revenue $0.50B → $1.30B
Within Latin America, Mexico accounts for 27.8% of regional revenue and 1.2% of the global total, worth USD 0.5 billion in 2025 and USD 1.3 billion by 2034.
Middle East and Africa Market Analysis
The 4th-largest region covered — 0.5 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 4 of 5
- 2025 share 4.5%
- By 2034 4%
- Revenue $1.90B → $3.60B
USD 1.9 billion of 2025 revenue is generated in Middle East and Africa, 4.5% of the global home infusion therapy services market rising to USD 3.6 billion in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 4% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the type split tracks the global one; 44.05% of 2025 revenue in Infusion pump, fastest growth of 9.61% in Needleless catheter. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.7×.
- In region 1 of 2
- Of region 36.8%
- Of global 1.7%
- Revenue $0.70B → $1.20B
USD 0.7 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 1.2 billion by 2034. At 36.8% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 1.9 billion in 2025 and USD 3.6 billion in 2034, it is the country the full report breaks out in detail.
The type pattern in Saudi Arabia is the global one: 44.05% of 2025 revenue in Infusion pump, 45.99% by 2034, against 9.61% growth in Needleless catheter taking it from 20.95% to 21.95%. With 36.8% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Saudi Arabia is reported separately in the full report.
In Saudi Arabia, infusion pumps and related devices used in home infusion therapy are regulated by the Saudi Food and Drug Authority, which requires medical device establishment licensing, product registration in the national device registry, and classification according to risk before marketing is permitted. Home healthcare providers must be licensed by the Ministry of Health and often seek accreditation from the Central Board for Accreditation of Healthcare Institutions to demonstrate compliance with clinical and safety standards for services delivered in a patient's home. Labelling and packaging of infusion products must meet Saudi Food and Drug Authority requirements, including Arabic-language instructions and safety warnings.
The suppliers tracked in this study (ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc.) compete in Saudi Arabia across the type lines above. Two different problems sit on the same axis: holding Infusion pump at 44.05% of 2025 revenue, and taking Needleless catheter while it grows at 9.61%.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 21.1%
- Of global 1%
- Revenue $0.40B → $0.80B
Within Middle East and Africa, South Africa accounts for 21.1% of regional revenue and 1% of the global total, worth USD 0.4 billion in 2025 and USD 0.8 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, component, end user, route of administration, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Infusion pump Volume and Needleless catheter Momentum
The suppliers covered are: ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc. and Accredo Health Group Inc..
The type axis, not the regional one, is where competition happens. The largest block of revenue is Infusion pump: USD 18.5 billion in 2025 at 44.05% of the total, 45.99% in 2034. Incumbency there is expensive to challenge. Movement is concentrated in Needleless catheter; 9.61% growth, against 7.98% at the other end of the axis in Intravenous set. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 42 billion.
Suppliers in home infusion therapy compete mainly on the size and reliability of their nursing and clinical staffing networks, the breadth of their payer contracting, and how much specialty pharmacy and compounding capability they carry alongside delivery and logistics reach. Companies that combine device or consumable manufacturing with service delivery hold an edge in payer contracting and can bundle equipment with care. Regional and single-state providers compete instead on established local clinical relationships, faster patient onboarding, and closer coordination with referring physicians rather than national scale.
The regional picture sets the entry cost: 43.3% of revenue is in North America and 26.9% in Europe, so a credible global position requires both, while Latin America at 4.3% can be served opportunistically.
The full report carries a profile, financials, share and development history for each company named; none of that is in this summary.
List of Key Home Infusion Therapy Services Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- ContinuumRx(United States)
- BioScrip Inc.(United States)
- BriovaRx Inc.(United States)
- CareCentrix Inc.(United States)
- Coram LLC(United States)
- Medical Services of America Inc.(United States)
- Cleveland Clinic(United States)
- Option Care Enterprises Inc.(United States)
- Allina Health(United States)
- ICU Medical Inc.(United States)
- Baxter International Inc.(United States)
- B. Braun Melsungen AG(Germany)
- Fresenius Kabi AG(Germany)
- Amerita Inc.(United States)
- Accredo Health Group Inc.(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, Component, End User, Route of Administration), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Home Infusion Therapy Services Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Home Infusion Therapy Services Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Home Infusion Therapy Services Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Home Infusion Therapy Services Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Home Infusion Therapy Services Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Home Infusion Therapy Services Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Home Infusion Therapy Services Market Size — Segment Comparison
Chapter 22.Global Home Infusion Therapy Services Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Home Infusion Therapy Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Home Infusion Therapy Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Home Infusion Therapy Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Home Infusion Therapy Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Home Infusion Therapy Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
3- 01Intravenous set
- 02Needleless catheter
- 03Infusion pump
By Application
10- 01Chemotherapy
- 02Diabetes
- 03Hydration therapy
- 04Inotropic therapy
- 05Pain management
- 06HIV therapies
- 07Post-transplant therapies
- 08Total parenteral nutrition
- 09Hemophilia therapies
- 10Others
By Component
3- 01Devices & Equipment
- 02Consumables
- 03Services
By End User
4- 01Home Care Settings
- 02Specialty Pharmacies
- 03Hospital-Based Home Infusion Providers
- 04Skilled Nursing Facilities
By Route of Administration
2- 01Central Venous Access
- 02Peripheral Venous Access
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
Sizing combines a bottom-up build from device and consumable unit volumes, tracking infusion pumps, administration sets and needleless connectors sold or leased into home infusion programs, together with per-patient service measures such as nursing visit frequency and average therapy duration by indication, with a top-down check against aggregate home healthcare and specialty pharmacy expenditure and the reimbursement spend payers report for home-administered infusion care. The two tracks are reconciled at the level of individual applications, such as parenteral nutrition, chemotherapy and antibiotic infusion, where device volume, service intensity and payer spend can be cross-checked against one another, with gaps resolved toward the measure supported by the more consistent disclosure across sources.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets commercial and procurement leads at specialty pharmacies and home health agencies, clinical directors who set nursing and care-coordination staffing levels, commercial teams at infusion device and consumable manufacturers, and payer and reimbursement policy staff who set coverage terms for home-administered therapy. Distribution and channel contacts are included where a market is served mainly through specialty pharmacy networks rather than direct provider relationships. Geographic sampling weights North America and Western Europe, where home infusion penetration and payer coverage are most developed, and supplements this with interviews across Asia Pacific and Gulf markets where home-based care delivery is expanding fastest.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Home Infusion Therapy Services Market projected to reach?
USD 91.1 Billion by 2034, CAGR 9.04%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 43.3% of global revenue through 2034.
05Which segment leads the market?
Infusion pump is the largest line by type, at 44.05% of revenue in 2025.
06Who are the key companies profiled?
ContinuumRx, BioScrip Inc., BriovaRx Inc., CareCentrix Inc., Coram LLC, Medical Services of America Inc., Cleveland Clinic, Option Care Enterprises Inc., Allina Health, ICU Medical Inc., Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Amerita Inc., Accredo Health Group Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.